Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Our highest priority is to continue to build on our leadership position in the Wound & Surgical markets by enhancing our product portfolio and expanding geographically |
| It's great to be able to report our strong fourth quarter and full year results with you all today |
| Our gross margin was 84%, reflecting a more than 300 basis point improvement from the fourth quarter of 2022 |
| I am very pleased to report that we had another outstanding quarterly performance in Q4, closing out an excellent 2023 |
| We continue to see solid growth in the hospital channel and other sites of service even in the face of tougher comps as we anniversaried the impact of products launched in late 2022 |
| We were really pleased with the progress we made throughout the course of the year, the number of physicians that were trained, the number of hospitals that started to bring the product on board, essentially all the largest wound care centers in the country are now touching the product |
| And together with our top line growth and strong EBITDA margins, we expect free cash flow conversion to continue to improve |
| And really the big event for us was late last summer when we suspended our knee OA program really improved our cash profile and cash generation |
| Doug Rice Again, pleased with our execution |
| As a result, we have made a dramatic improvement to our financial profile |
| I believe when we look back at 2023 in a few years, it will prove to be the seminal year and the company established a strong foundation, which was built upon for years to come |
| I have great confidence in the talented people I am fortunate to work with each day, and believe we are just getting started towards capitalizing on the many opportunities for us |
| We feel like there's room to improve with the great work that our quality operations regulatory team is doing and providing efficiencies |
| In the case of Q4, our 17% year-over-year growth rate was the fifth consecutive quarter of strong double digits growth we have seen and demonstrates both strong market adoption and a high level of commercial execution by our sales organization across each of our sites of service in the period |
| Q4 net sales grew year-over-year by approximately 17% to $87 million, another outstanding growth quarter |
| I think we're fairly well positioned |
| Gross profit margin improved to 84% in the quarter |
| I think the message though for you should be regardless of the outcome, we're probably better positioned than most people, if not all of our competitors in that setting |
| Our momentum continued with the successful commercial launch of EPIEFFECT into the private office setting |
| And as a result of multiple improvements we made to the business over the course of the year, we began 2024 with a far more attractive balance sheet than we had a year ago |
| So we have pretty good momentum in tailwinds all year in that setting |
| First, our focus on operational efficiency and building a culture of expense management discipline combined with the accelerated growth of the business led to improved cash flow generation and an increase in our cash balance throughout the course of the year |
| So we continue to capture share and also enjoy the market position that we're in with the market growth that we're experiencing |
| I would say that, while we are not going to give numbers on EPIEFFECT, we certainly enjoyed the launch and strong physician adoption of EPIEFFECT |
| We're super excited about just continued execution |
| Most importantly, our team is proud of the positive impact we make in the lives of countless people struggling with chronic and acute wound healing |
| The financial profile, our balance sheet, has much improved over the course of the year |
| We were $30 million positive there and excited to have the ability to reach back out for more dry powder with the new facility and the $75 million capacity if and when we need it |
| This reversal reflects our positive operating results during 2023 in concert with the reevaluation of our historical results, excluding our discontinued operations |
| Over the course of 2023, we posted consistently improving performance, culminating with the strong Q4 results we've just highlighted |
| Statement |
|---|
| Naturally, our prior year comps will become increasingly challenging as we progress into 2024 after achieving such outstanding results last year |
| As you can imagine, this situation slowed down the adoption of AXIOFILL, which is unfortunate given its impeccable safety profile and the patient benefit derived the product |
| First, as you may recall, Q3 was marked by confusion associated with an ill-fated attempt to introduce new local coverage determinations, or LCDs, for skin substitutes by three of the Medicare Administrative Contractors or MACs |
| Obviously, our comps are going to be a bit more challenging in 2024 but we did see very similar trends through the first part of the year, first part of quarter, I should say |
| Going back to some of the trends last quarter that given the sort of shifts that we saw from Novitas, First Coast and some other local MACs that there was a little bit of confusion there in terms of ordering patterns |
| But we knew that as we anniversaried new products, we were going to sort of slow that headline rate going into 2024 |
| If you would ask me earlier in 2023, if we could get the adjusted EBITDA margin to this level in less than a year, I would have considered that highly unlikely, given all of the things that would have had to fall in place to get that done |
| As you will recall, late in fourth quarter, we announced the receipt of a warning letter from the FDA relating to the regulatory classification of AXIOFILL, and only AXIOFILL |
| Later in the year, we had the proposed LCD that created some disruption and that settled down as well |
| We expect that to be much slower this year |
| We disagree with this position when it comes to AXIOFILL and do not believe the FDA has been consistent in the treatment of other human derived particulates |
| But I would expect that the first quarter would be our lowest returning to traditional seasonality and certainly the back half of the year will be the majority of our revenue |
| These expectations are subject to risks and uncertainties and actual results may differ materially from those anticipated due to many factors |
| So we are not really sure |
| What is the penetration rate? I know you have relatively low sales |
| So A, it would have to fit strategically and culturally, it would have to be accretive or lead to accretion in a given amount of time and we wouldn't overburden organization |
| From a cadence perspective, I would not expect the growth rate to be, I would expect, accelerating revenue as we get through the year and new products continue to ramp |
| So if you think about our cadence I think Q1 is going to be back to sort of the traditional seasonality there where Q1 deductibles, reset and things like that will be our lowest quarter and we'll finish with Q4 being our strongest quarter |
| We've got a lot of our legal issues behind us, professional fee spend and so on will go down |
Please consider a small donation if you think this website provides you with relevant information